A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: The princess margaret hospital phase II consortium

Clinical Lung Cancer

Volumn 15, Issue 1, 2014, Pages 52-57

  Laurie, Scott A ^a   Goss, Glenwood D ^a   Shepherd, Frances A ^b   Reaume, M Neil ^a   Nicholas, Garth ^a   Philip, Lindsay ^b   Wang, Lisa ^b   Schwock, Joerg ^b   Hirsh, Vera ^c   Oza, Amit ^b   Tsao, Ming Sound ^b   Wright, John J ^d   Leighl, Natasha B ^b  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

^d Cancer Therapy Evaluation Program   (United States)

Author keywords

Biomarker; Non small cell; Src inhibitor; Systemic therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; SARACATINIB;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CHILL; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSPNEA; EPISTAXIS; EXON; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; GENE DELETION; HEADACHE; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; INTERSTITIAL LUNG DISEASE; LUNG NON SMALL CELL CANCER; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RASH; SKIN DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; YOUNG ADULT;

BIOMARKER; NON-SMALL CELL; SRC INHIBITOR; SYSTEMIC THERAPY;

ADENOCARCINOMA; ADULT; AGED; BENZODIOXOLES; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SRC-FAMILY KINASES; SURVIVAL RATE;

EID: 84891830024     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.08.001     Document Type: Article

References (22)

1. F.A. Shepherd, J. Dancey, and R. Ramlau et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
2. N. Hanna, F.A. Shepherd, and F.V. Fossella et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
3. S.J. Parsons, and J.T. Parsons Src family kinases, key regulators of signal transduction Oncogene 23 2004 7906 7909
4. P.A. Bromann, H. Korkaya, and S.A. Courtneidge The interplay between src family kinases and receptor tyrosine kinases Oncogene 23 2004 7957 7968
5. J.M. Summy, and G.E. Gallick Src family kinases in tumor progression and metastasis Cancer Metastasis Rev 22 2003 337 358
6. T.P. Green, M. Fennell, and R. Whittaker et al. Preclinical anticancer activity of the potent, oral src inhibitor AZD0530 Mol Oncol 3 2009 248 261
7. P.R. Purnell, P.C. Mack, and C.G. Tepper et al. The src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells J Thor Oncol 4 2009 448 454
8. J. Baselga, A. Cervantes, and E. Martinelli et al. Phase I safety, pharmacokinetics, and inhibition of src activity study of saracatinib in patients with solid tumors Clin Cancer Res 16 2010 4876 4883
9. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
10. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10
11. A. Gucalp, J.A. Sparano, and J. Caravelli et al. Phase II trial of saracatinib (AZD0530), an oral src-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer Clin Breast Cancer 11 2011 306 311
12. H.J. Mackay, H.J. Au, and E. McWhirter et al. A phase II trial of the src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium Invest New Drugs 30 2012 1158 1163
13. F.M. Johnson, B.N. Bekele, and L. Feng et al. Phase II study of dasatinib in patients with advanced non-small lung cancer J Clin Oncol 28 2012 4609 4615
14. M.G. Fury, S. Baxi, and R. Shen et al. Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) Anticancer Res 31 2011 249 254
15. J. Arcaroli, K. Quackenbush, and A. Dasari et al. Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer Cancer Med 1 2012 207 217
16. P.N. Lara, J. Longmate, and C.P. Evans et al. A phase II trial of src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study Anticancer Drugs 20 2009 179 184
17. L. Song, M. Morris, and T. Bagui et al. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival Cancer Res 66 2006 5542 5548
18. E.B. Haura, T. Tanvetyanon, and A. Chiaporri et al. Phase I/II study of the src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer J Clin Oncol 28 2010 1387 1394
19. B. Sen, S. Peng, and X.M. Tang et al. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib Sci Transl Med 4 2012 136ra70
20. F.A. Shepherd, J.R. Pereira, and T. Ciuleanu et al. Erlotinib in previously-treated non-small-cell lung cancer N Eng J Med 353 2005 123 132
21. Johnson FM, Tang XM, Tran HT, et al. A phase I/II study combining dasatinib (D) and erlotinib (E) in non-small cell lung cancer. http://media3.asco.org/vod/vol2/132/8167/83448/83448-big-1.jpg (accessed June 28, 2013).
22. P.S. Hammerman, M.L. Sos, and A.H. Ramos et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer Cancer Discovery 1 2011 78 89